Landos Biopharma: Lanthionine Synthetase C-Like 2 (LANCL2) is a novel therapeutic target for autoimmune diseases, including inflammatory bowel disease (IBD); Crohn’s disease (CD) and ulcerative colitis (UC). Based on extensive preclinical studies, Landos has validated a unique mechanism of action involving LANCL2 that exerts potent anti-inflammatory effects with an outstanding safety profile. Successfully raised $60MM Series B in August 2019 with Perceptive and RTW.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - South Atlantic
Clinical Stage
Phase l or ll
Disease Space
Autoimmune
Listing
Private
Website:
Profiles:
Address:
1800 Kraft Drive SW
Suite 216
Blacksburg, VA 24060
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Lead Programs

BT-11

Indication Phase
LANCL2 2
LANCL2 1

NX-13

Indication Phase
NLRX1 IND
NLRX1 IND

BT-104

Indication Phase
LANCL2 Pre-clinical
LANCL2 Pre-clinical